Pharmacovigilance and Patient Compliance in Hypertensive Patients
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Study to confirm the safety profile of telmisartan (benefit-risk ratio) under normal
conditions of use after market launch and to supplement the present data on the safety of
telmisartan. Furthermore to assess effectiveness of a single dose of telmisartan per day to
control blood pressure for 24 hours, especially during the last few hours of the dosage
interval. Additionally to evaluate compliance with treatment, as an indirect measurement, and
to confirm the efficacy and possible risks associated with treatment.